The Genous stent is commercially available in more than 60 countries since 2005.

The Genous stent is commercially available in more than 60 countries since 2005, has been a safe, effective a safe, effective alternative to drug – eluting stents and data data from more than 5,000 patients sponsored enterprise clinical studies. There is a growing body of evidence from multiple clinical studies that. The Genous stent is effective for patients who do not respond or can not tolerate, is long-term dual antiplatelet therapy.

The study included 178 consecutive patients percutaneous coronary intervention percutaneous coronary intervention for de novo bifurcation lesion with a Genous stent and underwent 465 consecutive patients BMS BMS.. The cumulative rate of the primary endpoint, the composite of cardiac death, myocardial infarction or target lesion revascularization at one year follow-up was 12.4 percent for patients with a Genous stent BMS a 30 percent reduction to 17.2 percent in the control group were treated with BMS. The definite or probable stent thrombosis was 1.7 percent for the Genous stent patient group compared to 3.4 percent for the BMS treated patient group.Study restrictions contained self-reported tea and coffee consumption and the lack of specific information on the type of tea participants drank , however, E discontinued 78 per cent of the total of tea consumed. In the Netherlands and green tea, 4.6 per cent tea and coffee drinker very diverse health behaviors, the researchers note of Many coffee drinkers tend well as smoke and have a lesser healthy diet compared to tea drinking.

Co-authors are: Y. Margot de Koning goose, disc; Cuno SPM Uiterwaal. Joline WJ Beulens; Jolanda View MA Boer, Diederick E. Grobbee, and World Monique Verschuren, author specifications and sources of funding are in study.